Dermatomyositis News and Research

Latest Dermatomyositis News and Research

New classification criteria offers faster, more accurate path to diagnosing myositis diseases

The ability to diagnose myositis diseases and treat them properly just improved immensely. For more than 40 years, the criteria physicians have used to diagnose most myositis diseases has been based on expert opinion, not hard science.

21 Dec 2017

Endurance training can be helpful in dealing with muscle inflammation

Endurance training can actually be helpful in dealing with muscle inflammation, according to a new paper co-written by faculty at Binghamton University, State University of New York, and Karolinska Institutet and Karolinska University Hospital in Stockholm, Sweden.

8 Nov 2017

New treatment reduces disease burden in patients with rare dermatologic condition

A new treatment for a rare and often incurable condition called dermatomyositis (DM) reduced the severity of the disease in patients whose DM was resistant to other therapies.

31 Oct 2017

Exoskeleton device helps man with disabling condition to complete 10K race

Martin Jarry was a police officer in Quebec. He coached a youth hockey team. He was used to being active, used to working out, used to being strong. But when Jarry was diagnosed with inclusion body myositis (IBM), he had to do some serious re-evaluating of his activities.

10 Aug 2017

Statin medications can cause necrotizing myopathy in some patients

Statin medications, such as Crestor, Lipitor, and other lipid-lowering medications, have been prescribed increasingly in recent years to reduce cardiovascular disease and mortality in high risk individuals.

6 Jun 2017

Researchers develop ultrasensitive method to detect protein involved in autoimmune diseases

Researchers in France have developed a new method that will allow doctors to detect minute amounts of a protein called interferon-a in patient samples.

18 Apr 2017

Health care resource use and costs of H.P. Acthar® gel for multiple sclerosis relapse

Mallinckrodt plc, a leading global specialty biopharmaceutical company, today announced new retrospective health economic data on H.P. Acthar® Gel (repository corticotropin injection; RCI), which may be an option for the management of multiple sclerosis (MS) relapses.

6 Jul 2016

Anti-TNF therapy offers new hope to JDM patients

The results of a UK study presented today at the European League Against Rheumatism Annual Congress showed that tumour necrosis factor inhibitor (anti-TNF) treatment is effective at improving both muscle and skin involvement in children with juvenile dermatomyositis (JDM).

13 Jun 2016

African-American patients with connective tissue diseases at risk for cardiovascular disease

A study based on medical records from more than a quarter million adult patients found that African-American patients with connective tissue diseases such as lupus or rheumatoid arthritis were twice as likely as white patients to suffer from narrowed or atherosclerotic blood vessels, which increase the risk of a heart attack, stroke or death.

5 Feb 2016

Idera begins enrollment in IMO-8400 Phase 2 clinical trial for treatment of dermatomyositis

Idera Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing Toll-like receptor (TLR) and RNA therapeutics for patients with cancer and rare diseases, today announced that the company has commenced enrollment in a Phase 2 clinical trial of IMO-8400, an investigational TLR 7, 8 and 9 antagonist, in patients with dermatomyositis. Dermatomyositis is a rare and debilitating inflammatory muscle and skin disease associated with significant morbidity, decreased quality of life and an increased risk of premature death.

10 Nov 2015

Clinical study data on Mallinckrodt's H.P. Acthar Gel to be presented at ACR 2015

Mallinckrodt plc, a leading specialty biopharmaceutical company, today announced that data from a pilot study for its H.P. Acthar Gel (repository corticotropin injection) will be presented at the American College of Rheumatology 2015 Annual Meeting to be held November 7-11 in San Francisco.

8 Oct 2015

Former all-American wrestler speaks about his personal battle with chronic muscle disease

In 2009, Mike Powell was where he'd always wanted to be. A former all-American wrestler himself, he'd returned to his Chicago-area high school to become the toughest wrestling coach around, inspiring young athletes with a brutal mix of love and punishing workouts.

2 Sep 2015

Researchers identify link between autoimmune diseases, medications and Long QT syndrome

Mohamed Boutjdir, PhD, professor of medicine, cell biology, and physiology and pharmacology at SUNY Downstate Medical Center, has led a study with international collaborators identifying the mechanism by which patients with various autoimmune and connective tissue disorders may be at risk for life-threatening cardiac events if they take certain anti-histamine or anti-depressant medications.

7 Jul 2015

Idera collaborates with TMA to advance new potential treatment approach for myositis

Idera Pharmaceuticals, Inc., a clinical stage biopharmaceutical company developing nucleic acid therapeutics for patients with cancer and rare diseases, and The Myositis Association (TMA), the only nonprofit organization dedicated to solely serving all patients with inflammatory myopathies, today announced a collaboration to advance a new potential treatment approach for polymyositis and dermatomyositis known as Toll-like receptor (TLR) antagonism.

7 Aug 2014

Dermatomyositis News and Research

Latest Dermatomyositis News and Research

New classification criteria offers faster, more accurate path to diagnosing myositis diseases

Endurance training can be helpful in dealing with muscle inflammation

New treatment reduces disease burden in patients with rare dermatologic condition

Exoskeleton device helps man with disabling condition to complete 10K race

Statin medications can cause necrotizing myopathy in some patients

Researchers develop ultrasensitive method to detect protein involved in autoimmune diseases

Health care resource use and costs of H.P. Acthar® gel for multiple sclerosis relapse

Anti-TNF therapy offers new hope to JDM patients

African-American patients with connective tissue diseases at risk for cardiovascular disease

Idera begins enrollment in IMO-8400 Phase 2 clinical trial for treatment of dermatomyositis

Clinical study data on Mallinckrodt's H.P. Acthar Gel to be presented at ACR 2015

Former all-American wrestler speaks about his personal battle with chronic muscle disease

Researchers identify link between autoimmune diseases, medications and Long QT syndrome

Idera collaborates with TMA to advance new potential treatment approach for myositis

Baylor receives $3.3M grant from NIAMS to advance research in autoimmune diseases

Idera Pharmaceuticals reports positive top-line results from Phase 2 trial of IMO-8400

Researchers create specific tests to detect cancer biomarkers in patients with dermatomyositis

Questcor acquires rights to develop Synacthen and Synacthen Depot in US

Age at onset influences juvenile dermatomyositis course

Questcor second quarter net sales increase to $112.5 million

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Dermatomyositis News and Research

Latest Dermatomyositis News and Research

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Newsletters you may be interested in